Skip to main content
Premium Trial:

Request an Annual Quote

TGen, INMEGEN, Deltagen, Pyrosequencing, MiraiBio, Transgenomic, DNAPrint, Orchid Bioscience

Premium

TGen, INMEGEN to Research Gastric Cancer in Hispanics

The Translational Genomics Research Institute and the Institute of Genomic Medicine in Mexico will research diseases that affect Hispanics. The groups’ first focus will be gastric cancer, the second-leading cause of malignant tumors in Mexico.

Other diseases to be explored include diabetes. TGen said the arrangement with INMEGEN is its first international partnership.


Deltagen Equipment Goes on the Block

Deltagen, which filed for Chapter 11 bankruptcy protection in June, will auction the lab equipment from its 132,000-square foot Redwood City, Calif., facility on Oct. 15 and 16.

A pre-auction sale of the equipment — which includes Applied Biosystems gene sequencers, Agilent microarray scanners, autoclaves, sterilizers, test equipment, optical inspection equipment, IT equipment, and executive office furnishings — began on Aug. 15, Deltagen said last week.

The pre-auction sale and the live auction event are by order of the US Bankruptcy Court, Northern District of California. According to Nuri Otus, CEO of AuctioNet, the Deltagen auction will be “the largest sales event the biotechnology industry has ever seen.”

The live auction will be held at Deltagen’s facility and will also be featured on eBay’s Business & Industrial Live Online Auctions.


Pyrosequencing to Hold General Meeting in September on Personal Chemistry Question

Pyrosequencing’s board called for a general meeting to decide the disposition of the more than 23 million shares in Personal Chemistry, which Pyrosequencing will acquire on Sept. 25.

At the meeting, scheduled to take place on Sept. 25, Pyrosequencing’s board will propose that the company issue a maximum of 23.2 million ordinary shares, debentures with a maximum of 11.5 million warrants, and an authorization for the board to issue additional shares and debentures.

Once the merger is finalized, Personal Chemistry’s shareholders will control 40 percent of the share capital and votes in Pyrosequencing.

Uppsala, Sweden-based Pyrosequencing on Aug. 7 had agreed to buy 94.1 percent of Personal Chemistry’s shares, and to purchase the remaining shares through a separate agreement with the holders of options in Personal Chemistry. Personal Chemistry is also based in Sweden. Separately, Pyrosequencing announced several executive changes resulting from the acquisition [see page 2].


MiraiBio to Distribute Gentra’s Autopure Nucleic Acid Purification System in US

Hitachi Software Engineering unit MiraiBio will distribute Gentra Systems’ Autopure LS automated large sample nucleic acid-purification system and related consumables in the United States and other American territories.

Customers that require manual sample preparation can obtain other purification products from Gentra.


Transgenomic Announces $4.5M Private Placement

Transgenomic has signed securities purchase deals worth $4.5 million with a number of select investors, the company said last week.


DNAPrint to Serve as Genotyping Subcontractor for NIJ Project

An undisclosed grantee has hired DNAPrint Genomics to map genetic markers for a research project funded by the US National Institute of Justice, the R&D arm of the US Department of Justice.

DNAPrint said it would receive around $50,000 to produce approximately 80,000 genotypes for the project.


Scotland Yard Chooses Orchid Cellmark for DNA-Testing Help

London’s Metropolitan Police Service has chosen Orchid Biosciences’ European Cellmark division to provide scene-of-crime forensic DNA-testing services, Orchid said this week.

The three-year contract, extendable for an additional two years, was awarded through Orchid’s partner Forensic Alliance. Orchid said it expects to earn the equivalent of several million dollars annually in revenue.

The Metropolitan Police Service, headquartered at New Scotland Yard, London, is the UK’s largest police force, and is responsible for approximately 20 percent of all forensic testing in England and Wales.

Further details of the agreement were not disclosed, but the deal is believed to be the largest ever awarded to a private forensic laboratory in the UK.

 

Filed under

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.